Blood biomarker may spot lung scarring early
NCT ID NCT03457935
First seen Jan 05, 2026 · Last updated May 22, 2026 · Updated 21 times
Summary
This study looks at whether a molecule called miR200 in the blood can help identify early-stage idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. Researchers will compare blood samples from 450 people, including those with IPF, other lung diseases, and healthy volunteers. The goal is to find a simple blood test that could lead to earlier detection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Temple University
Philadelphia, Pennsylvania, 19140, United States
Conditions
Explore the condition pages connected to this study.